Transform the lives of patients in need of transplants

An increasing number of patients requiring organ transplants due to chronic and / or genetic diseases, coupled with needs for re-transplantation, has caused kidney transplant waitlists to grow. Severe side effects and the significant costs of immunosuppressants can create low adherence to treatment regimes, potentially leading to acute rejection episodes, and over time, graft failure. These unmet challenges, especially in kidney transplant, require a more sustainable solution.

Striving for improved health and longer-lasting tolerance after transplant

We aim to maintain organ function after surgery and reduce graft failures. Our chimeric immunotherapies have the potential to result in improved long-term tolerance for transplant recipients. A single-dose infusion of our personalized cell therapy product, delivered post-transplant, creates mixed chimerism. Our approach aims to curtail added stresses on all participants including recipients, donors, caregivers, and physicians.

See how we're making a difference in the lives of patients.

Combined with our gentler conditioning regime, which consists of low dose lymphoid irradiation and ATG administration, our approach helps patients avoid graft rejection and prolongs the life of the transplanted organ. By delivering a post-transplant conditioning regimen (versus pre-transplant), we are able to optimize receptivity to our single dose infusion. The Phase 2 clinical data showed patients reporting out beyond 10 years, and to this day are still without the use of immunosuppressive drugs and evidence of graft loss or rejection.

Our ongoing clinical studies show the possibility of reducing, or eliminating, the need for lifelong immunosuppressive drug therapy. We hope to bring the science behind our approach to other organ transplants and hematologic or immune diseases. Once implemented, our novel platform has the potential to improve the lives of patients and help reduce healthcare costs.

Learn more about our clinical trials.

HLA-Matched LDKT HLA-Mismatched LDKT Delayed Tolerance LDKT